Price
$15.61-70%1Y
1M-20%1Y-70%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageValue76
Quality25
Momentum30
Growth-
What they do
We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$1.41B
1Y Return-70%
5Y Return+57%
Raw charts
6 series · TTMAs reported to the SEC, without any scoring.